Xeris Biopharma Holdings (FRA:2B30) Current Deferred Taxes Liabilities : €0.0 Mil (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Xeris Biopharma Holdings's current deferred tax liabilities for the quarter that ended in Jun. 2024 was €0.0 Mil.

Xeris Biopharma Holdings Current Deferred Taxes Liabilities Historical Data

The historical data trend for Xeris Biopharma Holdings's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Current Deferred Taxes Liabilities Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Deferred Taxes Liabilities

Get a 7-Day Free Trial

Xeris Biopharma Holdings Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Current Deferred Taxes Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Xeris Biopharma Holdings Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (FRA:2B30) » Definitions » Current Deferred Taxes Liabilities

Comparable Companies

Traded in Other Exchanges

XERS:USA 0A8E:UK

Address

180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

Xeris Biopharma Holdings Headlines

No Headlines